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Erythrocytosis is an increase in the number of red blood cells.
In a recent study from the United States, the prevalence of
primary erythrocytosis (known as polycythaemia vera) was
44-57 per 100 000.1 The prevalence of secondary erythrocytosis
is considerably higher but is difficult to quantify owing to the
diversity of causes and paucity of data. This review aims to
provide an update on the diagnostic pathway for patients
presenting with erythrocytosis, as well as up to date appraised
data on the management of such patients.
What is the definition of erythrocytosis?
Erythrocytosis is suspected when haemoglobin is above 185
g/L or the packed cell volume is greater than 0.52 in a man or
165 g/L and 0.48, respectively, in a woman. The packed cell
volume is a measure of the volume percentage of red blood cells
in whole blood. In the past, the term polycythaemia was used
synonymously with erythrocytosis; however, this is incorrect
because polycythaemia implies an increase in all blood cells.2
An absolute or true erythrocytosis is present only when the red
cell mass (a highly specialised nuclear medicine test) is greater
than 125% of that predicted for sex and body mass. A red cell
mass test might show an absolute erythrocytosis or an apparent
erythrocytosis (normal red cell mass but reduced plasma
volume).
Factors associated with apparent erythrocytosis are obesity,
alcohol excess, smoking, and hypertension. Circumstantial
evidence from small non-randomised studies indicates that these
patients have increased morbidity and mortality.3-5 However, it
is not clear whether this increase is because of the raised packed
cell volume, and there are no randomised studies to show that
reducing the packed cell volume reduces morbidity or mortality.
A retrospective study found that in 30% of patients, packed cell
volume returns to normal with serial measurements,6 and
modification of risk factors such as smoking cessation can
reduce packed cell volume. Guidelines from the British
Committee for Standards in Haematology suggest that
venesection should be considered only in patients with a recent
thrombosis, additional risk factors for thrombosis, or a packed
cell volume greater than 0.54 (three standard deviations above
the mean).2
Why does erythrocytosis occur?
Regulation of erythropoiesis is a complex process that involves
oxygen sensing and the production of erythropoietin.
Erythrocytosis is defined as primary if a primary defect in the
erythroid compartment of the bone marrow leads to increased
red cell production and secondary if something external to the
bone marrow (usually erythropoietin) is produced in excess and
drives red cell production. For example, the most common cause
of acquired primary erythrocytosis is polycythaemia vera, where
patients have a mutation in the JAK2 gene. This leads to an
abnormal, constitutively active protein, which drives increased
production of red and white cells and platelets. Rare congenital
mutations in the erythropoietin receptor gene can also cause
primary erythrocytosis. A variety of rare genetic abnormalities,
such as mutations that cause high oxygen affinity haemoglobin,
can cause congenital secondary erythrocytosis. More common
conditions that underlie secondary erythrocytosis include
hypoxia from respiratory disease (the most common of these
secondary causes) and cardiac disease, renal disorders, and
exogenous administration of erythropoietin (box 1). When no
cause can be identified, the condition is termed idiopathic
erythrocytosis.
What are the clinical consequences of
erythrocytosis?
Apart from the risk of underlying disease that might need to be
treated, there is a well defined association between
erythrocytosis, rise in blood viscosity, and risk of thrombosis.
For example, the 34 year follow-up of the Framingham cohort
reported an association between being in the group with the
highest packed cell volume (five groups in total) and the risk
of cardiovascular mortality and morbidity.7 The multivariate
adjusted odds ratio for cardiovascular morbidity was 1.6
(P=0.0018) for women and 1.29 (P=0.019) for men aged 35-64
years who were in this group. Box 2 lists the symptoms of raised
blood viscosity.
The management of erythrocytosis needs to take into account
whether the rise in packed cell volume is a physiological
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Summary points
Erythrocytosis is a common reason for referral to haematology services and is usually secondary in origin
Referral thresholds for iron replete patients are packed cell volume persistently >0.52 in men and >0.48 in women
The cause can often be elucidated from a detailed medical and drug history
Common secondary causes include smoking, hypoxia, and diuretics
Intervention is not always indicated, and the decision to venesect is often made on a case by case basis after a risk-benefit assessment
True polycythaemia vera is rare. It carries an increased risk of thrombosis and progression to myelofibrosis or leukaemia and requires
specialist management
Sources and selection criteria
We searched PubMed to identify peer reviewed original articles, meta-analyses, and reviews. We considered only those papers that were
written in English, published from 1966 until the present day, which described studies that had adequate scientific validity. The authors’ own
collections and older references generated from initial papers were also examined. Randomised trials and series of patients and single case
reports were considered if appropriate.
Box 1 Causes of erythrocytosis in clinical practice
Common causes
Hypoxia: Smoking, lung or cardiac disease, sleep apnoea
Drugs: Diuretics, testosterone or anabolic steroids, erythropoietin
Polycythaemia vera
Rare causes
Primary erythrocytosis (intrinsic to the red cells): erythropoietin receptor mutation
Congenital forms of secondary erythrocytosis (extrinsic to the red cells)
Altered affinity of oxyhaemoglobin:
• High oxygen affinity haemoglobin
• Bisphosphoglycerate mutase deficiency
• Methaemoglobinaemia
Oxygen sensing pathway defects:
• VHL gene mutation (Chuvash erythrocytosis)
• PHD2 mutations
• HIF2A mutations
Acquired forms of secondary erythrocytosis (extrinsic to the red cells)
Central hypoxic process:
• Carbon monoxide poisoning
• High altitude habitat
Local renal hypoxia:
• Renal artery stenosis
• End stage renal disease
• Hydronephrosis
• Renal cysts (polycystic kidney disease)
• Post-renal transplant erythrocytosis
Pathological erythropoietin production:
• Cerebellar haemangioblastoma
• Meningioma
• Parathyroid carcinoma or adenoma
• Hepatocellular carcinoma
• Renal cell carcinoma
• Pheochromocytoma
• Uterine leiomyoma
Idiopathic erythrocytosis
response. For example, in cyanotic heart disease, the
physiological response to hypoxia is an increase in red cell
production, which aids oxygen delivery, so treatment of
erythrocytosis in this situation could worsen oxygen delivery
to the tissues and the patient’s symptoms, such as breathlessness.
How should erythrocytosis be
investigated in primary care?
Erythrocytosis is often discovered incidentally. The full blood
count should be repeated to see whether the rise is transient
(minimum of one week interval). As well as repeating the test,
look to see if it has been done in the past and whether the raised
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Box 2 Symptoms of hyperviscosity
Chest and abdominal pain
Myalgia and weakness
Fatigue
Headache
Blurred vision or symptoms to suggest amaurosis fugax
Paraesthesia
Slow mentation, sense of depersonalisation
packed cell volume is a new finding or whether the trend has
been present for while. If present for some time, this suggests
a true erythrocytosis. Once-off borderline increases in packed
cell volume often return to the normal range when patients are
reviewed in the haematology clinic.
Undertake a clinical history and examination to search for the
more common causes of a raised packed cell volume (box 1)
and to look for symptoms related to raised blood viscosity (box
2). Ask about smoking and alcohol history; use of thiazide
diuretics, testosterone, and anabolic steroids or any recent
change in drugs that coincides with the increase in packed cell
volume; and symptoms suggestive of obstructive sleep apnoea,
such as daytime somnolence. Erythrocytosis as a result of serious
medical comorbidities—such as cyanotic congenital heart
disease or renal transplantation—is usually apparent from the
medical history.
Initial investigations that can be performed in primary care to
help identify the cause of persistently raised packed cell volume
include pulse oximetry (for hypoxia) and urine dipstick (renal
causes). Refer patients with haematuria or hypoxia to the
appropriate specialists (figure⇓).
What investigations will be carried out in
the hospital setting?
Refer patients with persistent haemoglobin concentration or
packed cell volume above the upper limit of normal and no
obvious cause (box 1) to a haematologist for further
investigation (box 3). Urgently refer patients with polycythaemia
(raised white blood cell and platelet counts in addition to packed
cell volume) and those with symptoms of raised viscosity (box
2). The diagnosis of these patients has been radically altered by
the description of a mutation in JAK2, known as JAK2 V617F,
because more than 95% of those with polycythaemia vera test
positive for this mutation.8 9
Patients with erythrocytosis need to be divided into those with
a likely secondary cause, such as smoking or the recent addition
of thiazide diuretic, and those with no clear cause (see box 3).
JAK2 testing is performed in patients without a clear cause in
whom polycythaemia vera is likely. Baseline investigations for
erythrocytosis in the haematology clinic include a blood film
to look for features of myeloproliferative disease, such as
basophilia; serum ferritin (because iron deficiency can mask
the degree of erythrocytosis); and renal and liver profiles, to
look for undiagnosed renal or hepatic disease (which can cause
erythrocytosis; box 1). An abdominal ultrasound is often
performed to assess for splenomegaly. An enlarged spleen is
seen radiographically in two thirds of patients with
polycythaemia vera, although this may not be clinically
palpable.10 Ultrasound should be performed in all patients with
a high index of suspicion of having polycythaemia vera and
those with confirmed disease.
If JAK2 testing is negative, measurement of serum erythropoietin
can be helpful. A low value suggests a primary bone marrow
disease and should prompt testing for the rarer exon 12mutation
of JAK2, which is present in 2% of patients with polycythaemia
vera. Bone marrow aspiration and trephine biopsy should also
be considered. If erythropoietin is raised, a cause of exogenous
production of erythropoietin (box 1) should be sought. For
patients without a JAK2 mutation and normal erythropoietin,
the next step is usually measurement of red cell mass—the
definitive way to determine whether a true erythrocytosis exists.
Bone marrow aspiration and trephine biopsy should also be
considered, as well as investigation for rare mutations (box 1).
How is primary erythrocytosis managed?
British Committee for Standards in Haematology guidelines
recommend that patients are individually managed according
to their symptoms.2 Polycythaemia vera is a rare
lymphoproliferative disorder and patients have a 1.6 greater risk
of thrombosis compared with the general population, so the
main aim of treatment is to prevent thrombosis; paradoxically,
haemorrhage may also be a problem, but this is usually confined
to patients with severe thrombocytosis. The mechanism is not
entirely clear, but it may be caused by acquired vonWillebrand’s
disease. Patients with polycythaemia vera need long term
follow-up in a specialist clinic. This is not only to manage
cytoreductive treatment but to monitor signs of disease
progression to the myelofibrotic stage (the “burnt out” phase,
where the bone marrow is replaced by dense fibrous bands of
reticulin and cytopenias are common, the incidence varying
from 6% to 15% at 15 years).11 12 Using evidence based risk
factors, patients with polycythaemia vera are stratified into those
at low, intermediate, or high risk of thrombosis according to
age, history of thrombosis, and cardiovascular risk factors.
Patients can also have a raised platelet count and white cell
count, which will increase the risk of thrombosis further.13
Cytoreductive treatment, which reduces packed cell volume as
well as the numbers of leucocytes and platelets, is indicated for
those with high risk disease but not usually for those with low
risk disease. Treatment decisions for patients falling into the
intermediate risk categories are decided on a case by case basis.
Venesection (usually 450 mL of blood; to maintain a target
packed cell volume <0.45), together with low dose aspirin, is a
mainstay of treatment in polycythaemia vera. Until recently,
the only randomised study to compare phlebotomy with
cytoreductive treatment was performed more than 30 years ago
(PVSG-01 trial).14 In early 2013, the CYTO-PV Collaborative
Group published the results of a large well conducted
randomised trial. It found that patients with polycythaemia vera
and a packed cell volume target of less than 0.45 had a
significantly lower rate of death from cardiovascular disease
and major thrombosis than did those with a target of 0.45-0.50
(4.4% v 10.9%; hazard ratio 2.69, 95% confidence interval 1.19
to 6.12; P=0.02).15 The ECLAP study, a double blind placebo
controlled randomised trial of 518 patients, confirmed the safety
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Box 3 What the haematologist will do
Initial investigations
Repeat full blood count and blood film
Iron studies/ferritin
Serum erythropoietin concentration
JAK2 mutation
Oxygen saturations and urine dipstick (if not previously done)
Renal and liver profile (if not previously done)
Secondary investigations
Abdominal ultrasound
Chest radiography
Referral for sleep study or lung function
Bone marrow aspirate and trephine
Measurement of red cell mass
JAK2 exon 12 mutation
Erythropoietin receptor gene analysis
VHL analysis
and efficacy of aspirin in polycythaemia vera.16 Treatment with
aspirin as compared with placebo reduced the risk of the
endpoint of non-fatal myocardial infarction, non-fatal stroke,
pulmonary embolism, major venous thrombosis or death from
cardiovascular cause (relative risk 0.4; P=0.03). The incidence
of major bleeding episodes was not significantly increased in
the aspirin group.16
Several cytoreductive agents are used to treat high risk
polycythaemia vera, some of which—such as busulfan and
hydroxycarbamide (hydroxyurea)—have a long established role;
others, such as Janus kinase (JAK) inhibitors, are novel and
emerging treatments whose roles are yet to be clearly defined.
Hydroxyurea (ribonucleotide reductase inhibitor) is the first line
cytoreductive agent for the treatment of high risk polycythaemia
vera in patients over the age of 60 years.2 There is controversy
surrounding the potential leukaemogenicity of this agent because
acute myeloid leukaemia is part of the natural course of
polycythaemia vera. Small studies report a variable risk of
leukaemia, but larger studies have found that the risk is no
different from that of untreated patients.17 18However, it is clear
that, over time, the use of multiple cytotoxic agents with
leukaemic potential together with hydroxyurea increases the
risk of transformation to leukaemia. Data from a long term
follow-up study showed that at 10, 15, and 20 years, the
cumulative incidence of acute myeloid
leukemia/myelodysplastic syndrome was 6.6%, 16.5%, and
24% in patients randomised to hydroxyurea and 13%, 34%, and
52% in the pipobroman arm (P=0.004).19 Alternative
cytoreductive agents are considered in young patients, such as
interferon alfa, which is not teratogenic or leukaemogenic.
Busulfan is an alkylating agent, and the European LeukaemiaNet
guidelines suggest that its use should be limited to patients over
65 years owing to its well documented leukaemogenicity,
especially when used sequentially with other agents, as is also
the case for pipobroman.20
How is secondary erythrocytosis
managed?
Congenital erythrocytosis
Rare congenital defects of haemoglobin, such as haemoglobin
with a high affinity for oxygen, have been described. Affected
patients have a variable phenotype but usually need treatment
only if they develop viscosity-like symptoms (see box 2). Other
congenital secondary causes include defects in the oxygen
sensing pathway, such as VHL gene mutation (Chuvash
erythrocytosis). Congenital erythrocytosis should be managed
by a specialist haematology service. The mainstay of treatment
in these patients will be venesection.
Hypoxia driven erythrocytosis
Cyanotic heart disease, pulmonary disease, and smoking can
all cause an erythrocytosis as a compensatory mechanism in
response to hypoxia. The challenge with these patients is to
balance oxygen delivery against the effects of hyperviscosity
from a raised packed cell volume. In patients with hypoxic
pulmonary disease, the development of erythrocytosis is
associated with an increased risk of cor pulmonale and a median
survival of two to three years.21 A Cochrane review confirmed
that long term oxygen therapy reduces mortality in patients with
chronic obstructive pulmonary disease and severe hypoxia (peto
odds ratio of 0.45 and 0.42 for the two main randomised
controlled trials).22 Long term oxygen therapy also reduces
packed cell volume by improving oxygenation.23-25 Therefore,
patients with pulmonary driven erythrocytosis should be referred
to a specialist respiratory doctor for consideration of treatments
to improve oxygenation and tackle the underlying cause for the
compensatory erythrocytosis.
Obstructive sleep apnoea can also cause erythrocytosis, and
these patients should also be reviewed by a respiratory doctor.
Evidence from small case series suggests that venesection should
be considered in patients who have symptoms associated with
hyperviscosity or a packed cell volume greater than 0.56; a
target packed cell volume of 0.50-0.52 has been shown to
improve exercise tolerance.2 26-29
In cyanotic congenital heart disease a compensatory
erythrocytosis develops to maintain delivery of oxygen to the
tissues. As the packed cell volume increases, symptoms of
hyperviscosity may develop, although many patients remain
symptom free even when the packed cell volume is greater than
0.70.30 31 Themanagement of these patients is complex and they
should be managed in a unit with an interest in cyanotic
congenital heart disease. Venesection should be performed only
in those with symptoms and in an isovolaemic manner, with a
target decided on a case by case basis.2
A raised packed cell volume is well documented after renal
transplantation, being seen in 10-15% of patients at 24 months.
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This increase has a multitude of causes, and it is associated with
considerable morbidity. A review of 53 cases of erythrocytosis
after renal transplantation reported an increase in
thromboembolic events (18.9%) compared with transplant
recipients without a raised packed cell volume (0%), although
this finding is not consistent among all studies.32 Prospective
randomised studies show that these patients usually respond
well to angiotensin converting enzyme inhibitors or angiotensin
receptor blockers, leading to a reduction in the packed cell
volume within three months.33 34 Every measure should be taken
to avoid dehydration in these patients by the judicious use of
diuretics and rehydration if diarrhoea or vomiting occurs.
Patients who do not respond to angiotensin converting enzyme
inhibitors or angiotensin receptor blockers can be venesected
to a target packed cell volume of less than 0.45, but iron
deficiencymay become a problem. As is the case in all instances
of erythrocytosis, iron replacement therapy may be used
judiciously, but the packed cell volume must be closely
monitored. Adenosine facilitates the release of erythropoietin
and is also thought to influence the bone marrow response to
erythropoietin. In a study of eight patients with erythrocytosis
after renal transplantation and five healthy controls, an eight
week course of theophylline significantly reduced serum
erythropoietin and packed cell volume in both groups.35However
the reduction in erythrocytosis in response to theophylline is
less predictable than that seen with angiotensin converting
enzyme inhibitors or angiotensin receptor blockers, and detailed
outcome data for the use of all of these agents are lacking.
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Additional educational resources
Resources for healthcare professionals
British Committee for Standards in Haematology (www.bcshguidelines.com)—Guidelines for the diagnosis, investigation, andmanagement
of haematological diseases, including polycythaemia and erythrocytosis
Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst
Rev 2005;4:CD001744. Review that includes the evidence for oxygen therapy reducing hypoxia driven erythrocytosis
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in
polycythemia vera. N Engl J Med 2013;368:22-33. An important paper guiding therapeutic targets in polycythaemia
Resources for patients:
MPD Voice (www.mpdvoice.org.uk)—Patient charity that provides information on polycythaemia vera including diagnosis, treatment,
and clinical trials
Figure
Diagnostic pathway for general practitioners in patients with erythrocytosis
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